Stay updated on Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial

Sign up to get notified when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision v3.4.3 has been added to the history, and the v3.4.2 entry has been removed.
    Difference
    0.1%
    Check dated 2026-03-11T17:56:15.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added to the page history, and the previously displayed funding-lapse notice (v3.4.1) was removed. The overall interface and listed study records remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2026-02-11T09:24:12.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding and NIH operations. Introduced revision v3.4.1; the previous revision v3.4.0 is removed from the history.
    Difference
    0.5%
    Check dated 2026-02-04T05:51:31.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a glossary toggle and color-coded change highlights (green for additions, red for deletions) on the history page. The revision label was updated to v3.4.0 and the No FEAR Act Data text was adjusted.
    Difference
    0.7%
    Check dated 2026-01-28T04:14:58.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    A new revision entry, Revision v3.3.4, appears in the history. Revision v3.3.3 is removed from the list.
    Difference
    0.1%
    Check dated 2026-01-14T03:17:18.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    A new Revision: v3.3.3 has been added, and the HHS Vulnerability Disclosure link along with Revision: v3.3.2 has been removed.
    Difference
    0.1%
    Check dated 2025-12-23T21:06:43.000Z thumbnail image

Stay in the know with updates to Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Canakinumab & Pembrolizumab Combo in Early NSCLC Clinical Trial page.